Biomarkers to Monitor Safety in People on ART and Risk of Mortality
Authors:
- Loveleen BansiLBLoveleen Bansi
- Brian GazzardBGBrian Gazzard
- Frank PostFPFrank Post
- Andrew PhillipsAPAndrew Phillips
- Margaret JohnsonMJMargaret Johnson
- Teresa HillTHTeresa Hill
- Richard GilsonRGRichard Gilson
- Clifford LeenCLClifford Leen
- John WalshJWJohn Walsh
- Martin FisherMFMartin Fisher
- Caroline SabinCSCaroline Sabin
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 60 (1) , 51-58
Abstract
Introduction: Though patients with HIV now have near normal life expectancies as a result of antiretroviral treatment, long-term adverse effects are of growing concern. Using time-updated laboratory measurements, we use several methods to derive a score that can be used to identify individuals at high risk of mortality. Methods: Patients who started highly active antiretroviral therapy after 2000 and had ≥1 CD4 count, viral load, and laboratory marker recorded after the date of starting highly active antiretroviral therapy were included in the analyses. Laboratory markers were stratified into quintiles and associations between each marker and mortality was assessed using Poisson regression. The estimates of the final model were used to construct a score for predicting short-term mortality. Several methods, including multiple imputation, were used for analyzing records with missing measurements. Results: Of the 7232 patients included in this analysis, 247 died over 24,796 person-years of follow-up, giving an overall mortality rate of 1.00 (95% confidence interval: 0.87 to 1.12) per 100 person-years. Regardless of which method was used to deal with missing data, albumin, alkaline phosphatase, and hemoglobin were independently associated with mortality. Alanine transaminase was independently associated with mortality when patients with missing measurements were assumed to have measurements within the normal range. The C-statistics for all models ranged from 0.76 to 0.78. Conclusion Measures of alanine transaminase, albumin, alkaline phosphatase, and hemoglobin in the normal range were predictive of mortality, and hence we suggest using a scoring system to predict mortality which relies on the raw values of these 4 laboratory markers.Keywords
This publication has 22 references indexed in Scilit:
- Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphataseAIDS, 2010
- Incidence of anaemia among HIV‐infected patients treated with highly active antiretroviral therapy*HIV Medicine, 2007
- Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender*HIV Medicine, 2007
- Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003HIV Medicine, 2005
- The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) StudyHIV Medicine, 2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination TherapyThe Journal of Infectious Diseases, 2002
- Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without StavudineClinical Infectious Diseases, 2000
- Human Immunodeficiency Virus‐Associated Dementia: Review of Pathogenesis, Prophylaxis, and Treatment Studies of Zidovudine TherapyClinical Infectious Diseases, 1999
- ASSOCIATION BETWEEN SERUM ALBUMIN AND MORTALITY FROM CARDIOVASCULAR DISEASE, CANCER, AND OTHER CAUSESThe Lancet, 1989